Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desmethylsertraline is an active metabolite of the antidepressant drug sertraline. It acts as a monoamine reuptake inhibitor, affecting serotonin, norepinephrine, and dopamine reuptake. This results in increased levels of these neurotransmitters in the synaptic cleft, which can enhance neurotransmitter signaling and contribute to therapeutic benefits. Desmethylsertraline is less potent than sertraline as a serotonin reuptake inhibitor but exhibits a more balanced effect across serotonin, norepinephrine, and dopamine reuptake, functioning as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desmethylsertraline.